Citation Impact
Citing Papers
Comparison of Two Fluid-Management Strategies in Acute Lung Injury
2006 Standout
voom: precision weights unlock linear model analysis tools for RNA-seq read counts
2014 Standout
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
2003 Standout
HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
1998
Untangling the ErbB signalling network
2001 Standout
Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study
2007
Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
1998
Alveolar epithelial type II cell: defender of the alveolus revisited
2001
Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
1999
c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.
1996
Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
1999
The EGF receptor family as targets for cancer therapy
2000
Spontaneous and pronase‐induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines
2012
Automated Assay for HER-2/neu in Serum
2000
From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells
1999
Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe
2001
Herceptin: mechanisms of action and resistance
2005
Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy
1998
Molecular Markers for Predicting Response to Tamoxifen in Breast Cancer Patients
2000
Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer
2002
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells.
1999
Overexpression of the HER-2/ neu Oncogene in Pancreatic Adenocarcinoma
2001
HER-2/neu and p53 Expression Versus Tamoxifen Resistance in Estrogen Receptor–Positive, Node-Positive Breast Cancer
2000
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
1999 Standout
The Predictive Value of HER2 in Breast Cancer
2001
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Intensity-based hierarchical Bayes method improves testing for differentially expressed genes in microarray experiments
2006
Elevated Serum HER-2/neu Level Predicts Decreased Response to Hormone Therapy in Metastatic Breast Cancer
2002
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
2001
The Prognostic Significance of c-erbB-2 Serum Protein in Metastatic Breast Cancer
1997
Serial serum c-erbB-2 levels in patients with breast carcinoma
1996
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer.
2003
Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm
2006
HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer
2004
Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots
2002 Standout
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Prognostic Factors in Breast Cancer
2000
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
2006 Standout
PGDS, A Novel Technique Combining Chromogenic In Situ Hybridization and Immunohistochemistry for the Assessment of ErbB2 (HER2/neu) Status in Breast Cancer
2007
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
2000 Standout
Small‐sample adjustments in using the sandwich variance estimator in generalized estimating equations
2002
Integrins in cancer: biological implications and therapeutic opportunities
2009 Standout
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
1998
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
2011 StandoutNature
Cancer drug resistance: an evolving paradigm
2013 Standout
Trastuzumab: triumphs and tribulations
2007
Genetic instabilities in human cancers
1998 StandoutNature
Radiomics: Images Are More than Pictures, They Are Data
2015 Standout
Molecular determinants of resistance to antiandrogen therapy
2003 Standout
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients
1997
Association of polymorphisms in the collagen region of SP-A2 with increased levels of total IgE antibodies and eosinophilia in patients with allergic bronchopulmonary aspergillosis
2003
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer
1998
Genetic Determinants and Ethnic Disparities in Sepsis-associated Acute Lung Injury
2005
The development of androgen-independent prostate cancer
2001 Standout
Heat Shock Protein A12B Protects Vascular Endothelial Cells Against Sepsis-Induced Acute Lung Injury in Mice
2017 Standout
Comparison of HER‐2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma
2005
Putting tumours in context
2001 Standout
Acute respiratory distress syndrome 40 years later: Time to revisit its definition*
2008
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Drug repurposing: progress, challenges and recommendations
2018 Standout
Targeting RAS signalling pathways in cancer therapy
2003 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Promoter analysis of TCDD-inducible genes in a thymic epithelial cell line indicates the potential for cell-specific transcription factor crosstalk in the AhR response
2008
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
1999
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
limma powers differential expression analyses for RNA-sequencing and microarray studies
2015 Standout
Tumour-educated macrophages promote tumour progression and metastasis
2004 Standout
Molecular targets for breast cancer therapy and prevention
2001
NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer
2000 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
Recent advances in genetic predisposition to clinical acute lung injury
2009
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Modern Synthetic Methods for Fluorine‐Substituted Target Molecules
2004 Standout
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers
1996
Immunity to fungal infections
2011 Standout
The acute respiratory distress syndrome
2012 Standout
The HER2 Extracellular Domain as a Prognostic and Predictive Factor in Breast Cancer
2002
Adipocytokines: mediators linking adipose tissue, inflammation and immunity
2006 Standout
New functions for the matrix metalloproteinases in cancer progression
2002 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Genetic polymorphisms in sepsis
2005
Breast cancer metastasis: markers and models
2005 Standout
Future Research Directions in Acute Lung Injury
2003
Pre–B-Cell Colony-enhancing Factor as a Potential Novel Biomarker in Acute Lung Injury
2004
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy
1998
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.
2000
ERBB2-Mediated Transcriptional Up-regulation of the α5β1 Integrin Fibronectin Receptor Promotes Tumor Cell Survival Under Adverse Conditions
2006
HER2 Testing in Breast Cancer: NCCN Task Force Report and Recommendations
2006
Acute Respiratory Distress Syndrome
2012 Standout
Robust Standard Errors in Small Samples: Some Practical Advice
2016 StandoutNobel
American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer
2005 Standout
Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects
2003 Standout
HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression
2001 StandoutNobel
Cytokine Storm
2020 Standout
2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*
2001
The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis
2018 Standout
Role of HER2 gene overexpression in breast carcinoma
2000
Identify potential drugs for cardiovascular diseases caused by stress-induced genes in vascular smooth muscle cells
2016
When Is a Tumor Marker Ready for Prime Time? A Case Study of c-erbB-2 as a Predictive Factor in Breast Cancer
2001
Elevated Serum HER-2/neu Level Predicts Decreased Response to Hormone Therapy in Metastatic Breast Cancer
2002
Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury
2007
HER2 as a Predictor of Therapeutic Response in Breast Cancer
2000
Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 2. Clinical Considerations and New Agents
2003
The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy
1998
Works of V. M. Chinchilli being referenced
Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
1995
Polymorphisms of human SP‐A, SP‐B, and SP‐D genes: association of SP‐B Thr131Ile with ARDS
2000
Small sample characteristics of generalized estimating equations
1995
Empirical Bayes Gene Screening Tool for Time-Course or Dose–Response Microarray Data
2004